Kratom Research 2025/2026: Where Do We Stand?
What We Know with High Confidence
- Mitragynine is the main alkaloid (typically up to 66% of alkaloid content)
- 7-OH-mitragynine has higher μ-MOR affinity in lab studies
- Both alkaloids are partial μ-opioid receptor agonists in preclinical models
- Dependence potential – withdrawal symptoms after regular use documented
What We Know with Moderate Confidence
- Kratom reduces classical opioid withdrawal symptoms in animal models
- Self-report surveys show significant proportion of users use kratom for opioid cessation
- Alkaloid profiles vary considerably by origin, harvest and processing
What We Do Not Know (Research Gaps)
- Safe dosage limits in humans – no clinically validated thresholds
- Long-term effects of regular kratom use
- Whether kratom is clinically effective as substitution therapy (missing RCTs)
- Complete drug interaction profile
Conclusion
The kratom research gap is partly the result of political blockades. Kratom deserves more serious research, not less.
Legal Notice: This article is for informational purposes only and does not constitute legal advice. The content is not intended to encourage consumption. Laws may change; the applicable regulations and information from official authorities shall prevail. Image source: https://www.kratoein.com/